Creativ-Ceutical, a strategic Pricing, Market Access and Health Economics consultancy for the life science industry has agreed with conference organiser NextLevel Pharma to exclusively sponsor their new conference on “Market & Patient Access for Chronic Disease Therapies”, to be held on 24-25 September in Vienna, Austria.
Health spending on chronic diseases is a long-term problem for payers who must prioritise their budgets in a difficult economic environment. Pharmaceutical manufacturers have a great opportunity to expand into this growing market; however access may be limited by budget restrictions, disease management plans and other payer priorities. Pharma marketers and health economists need to have a clear perspective of the objectives and perspectives of payers, HTAs, patient groups, as well as doctor and pharmacy associations, to successfully increase market and patient access in this area.
Visit www.nextlevelpharma.com/
This conference brings together payers and industry experts for two days of intensive discussion and debate, and attendees will gain fresh insight into these and other topics:
• Using disease management programmes to improve outcomes and market-access
• Using stakeholder mapping to build a value proposition for HTA reviews
• The real market conditions and opportunities in emerging European markets
• Today’
• Upcoming healthcare budget reforms across Europe.
Mondher Toumi, CEO of Creativ-Ceutical and Professor of Decision Sciences at the University Claude Bernard in Lyon, will speak at this event, on market access issues related to central nervous system (CNS) therapies. “CNS diseases are different from other chronic diseases and demand special attention. Payers and companies have fewer means of assessing outcomes for CNS drugs, and in a cost-constrained environment, these drugs are increasingly de-prioritised,”
Luke Rogers, CEO of NextLevel Pharma says: “We are proud to continue our working partnership with Creativ-Ceutical and look forward to their insight at our upcoming event which will bring all the stakeholders involved, from payers to patient groups and the industry, closer together."
